Dz13: c-Jun downregulation and tumour cell death

Chemical Biology and Drug Design

Volumn 78, Issue 6, 2011, Pages 909-912

  Elahy, Mina ^a   Dass, Crispin R ^a  

^a VICTORIA UNIVERSITY   (Australia)

Author keywords

Cancer; DNAzyme; Downregulation; Dz13; Therapy

Indexed keywords

CASPASE 2; DEOXYRIBOZYME; DOXORUBICIN; DZ13 DNAZYME; MESSENGER RNA; NANOPARTICLE; PROTEIN C JUN; TRANSCRIPTION FACTOR E2F1; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTERY INJURY; CELL DEATH; CELL MIGRATION; CELL PROLIFERATION; DOWN REGULATION; ENDOTHELIUM CELL; ENZYME ACTIVITY; HUMAN; INFLAMMATION; METASTASIS; NEOINTIMA; NONHUMAN; PRIORITY JOURNAL; REVIEW; TUMOR CELL;

ANIMALS; APOPTOSIS; CELL DEATH; DNA, CATALYTIC; DOWN-REGULATION; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PROTO-ONCOGENE PROTEINS C-JUN;

EID: 81355142738     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/j.1747-0285.2011.01166.x     Document Type: Review

References (32)

1. Dass C.R., Choong P.F.M. (2008) c-jun: a potential therapeutic target for multiple pathologies. Pharmazie;6:411-414.
2. Zhang G., Dass C.R., Sumithran E., Di Girolamo N., Sun L.Q., Khachigian L.M. (2004) Effect of Dz targeting c-Jun on solid tumor growth and angiogenesis in rodents. J Natl Cancer Inst;96:683-696.
3. Dass C.R., Galloway S.J., Choong P.F.M. (2010) A c-jun DNAzyme which is a potent inducer of caspase-2 activation. Oligonucleotides;20:137-146.
4. DeGregori J., Johnson D.G. (2006) Distinct and overlapping roles for E2F family members in transcription, proliferation and apoptosis. Curr Mol Med;6:739-748.
5. Iaquinta P.J., Lees J.A. (2007) Life and death decisions by the E2F transcription factors. Curr Opin Cell Biol;19:649-657.
6. Rivory L., Tucker C., King A., Lai A., Goodchild A., Witherington C., Gozar M.M., Birkett D.J. (2006) The DNAzymes Rs6, Dz13, and DzF have potent biologic effects independent of catalytic activity. Oligonucleotides;16:297-312.
7. Goodchild A., King A., Gozar M.M., Passioura T., Tucker C., Rivory L. (2007) Cytotoxic G-rich oligodeoxynucleotides: putative protein targets and required sequence motif. Nucleic Acids Res;35:4562-4572.
8. Gozar M.M., Goodchild A., Passioura T., King A., Lai A., Witherington C., Rivory L. (2008) Dz13, a DNAzyme targeting c-jun, induces off-target cytotoxicity in endothelial cells with features of nonapoptotic programmed cell death. Oligonucleotides;18:257-268.
9. Zhang G., Luo X., Sumithran E., Pua V.S., Barnetson R.S., Halliday G.M., Khachigian L.M. (2006) Squamous cell carcinoma growth in mice and in culture is regulated by c-Jun and its control of matrix metalloproteinase-2 and -9 expression. Oncogene;25:7260-7266.
10. Dass C.R., Khachigian L.M., Choong P.F.M. (2008) c-Jun knockdown sensitizes osteosarcoma to doxorubicin. Mol Cancer Ther;6:1289-1292.
11. Dass C.R., Friedhuber A.M., Khachigian L.M., Dunstan D.E., Choong P.F.M. (2008) Downregulation of c-jun results in apoptosis-mediated anti-osteosarcoma activity in an orthotopic model. Cancer Biol Ther;7:1033-1036.
12. Dass C.R., Galloway S.J., Clark J.C., Khachigian L.M., Choong P.F. (2008) Involvement of c-jun in human liposarcoma growth. Cancer Biol Ther;7:1297-1301.
13. Dass C.R., Khachigian L.M., Choong P.F. (2008) c-Jun knockdown sensitizes osteosarcoma to doxorubicin. Mol Cancer Ther;7:1909-1912.
14. Dass C.R., Ek E.T., Contreras K.G., Choong P.F. (2006) A novel orthotopic murine model provides insights into cellular and molecular characteristics contributing to human osteosarcoma. Clin Exp Metastasis;23:367-380.
15. Tan M.L., Friedhuber A.M., Dunstan D.E., Choong P.F., Dass C.R. (2010) The performance of doxorubicin encapsulated in chitosan-dextran sulphate microparticles in an osteosarcoma model. Biomaterials;31:541-551.
16. Tan M.L., Dunstan D.E., Friedhuber A.M., Choong P.F.M., Dass C.R. (2010) A nanoparticulate system that enhances the efficacy of the tumoricide Dz13 when administered proximal to the lesion site. J Control Release;144:196-202.
17. Dass C.R., Choong P.F.M. (2010) Sequence-related off-target effect of Dz13 against human tumour cells and safety in adult and foetal mice following systemic administration. Oligonucleotides;20:51-60.
18. Tinari A., Tinari A., Giammarioli A.M., Manganelli V., Ciarlo L., Malorni W. (2008) Analyzing morphological and ultrastructural features in cell death. Meth Enzymol;442:1-26.
19. Dass C.R., Tan M.L., Galloway S.J., Choong P.F.M. (2010) Dz13 induces a cytotoxic stress response with upregulation of E2F1 in tumour cells metastasising to or from bone. Oligonucleotides;20:79-91.
20. Fueyo J., Gomez-Manzano C., Yung W.K., Liu T.J., Alemany R., McDonnell T.J., Shi X., Rao J.S., Levin V.A., Kyritsis A.P. (1998) Overexpression of E2F-1 in glioma triggers apoptosis and suppresses tumor growth in vitro and in vivo. Nat Med;4:685-690.
21. Tan M.L., Choong P.F.M., Dass C.R. (2010) Direct anti-metastatic efficacy by the DNA enzyme Dz13 and downregulated MMP-2, MMP-9 and MT1-MMP in tumours. Cancer Cell Int;10:9.
22. Dass C.R., Friedhuber A.M., Khachigian L.M., Dunstan D.E., Choong P.F.M. (2008) Biocompatible chitosan-DNAzyme nanoparticles exhibits enhanced biological activities. J Microencapsul;25:421-425.
23. Ta H.T., Dass C.R., Larson I., Choong P.F., Dunstan D.E. (2009) A chitosan-dipotassium orthophosphate hydrogel for the delivery of doxorubicin in the treatment of osteosarcoma. Biomaterials;30:3605-3613.
24. DeCruz E.E., Walker T.L., Dass C.R., Burton M.A. (1996) The basis for somatic gene therapy of cancer. J Exp Ther Oncol;1:73-83.
25. Fahmy R., Dass C.R., Lipworth W., Zreiqat H., Sun L.Q., Chesterman C.N., Khachigian L. (2003) Early Growth Response factor-1: a key mediator of tumor angiogenesis and neovascularisation. Nat Med;9:1026-1032.
26. Mitchell A., Dass C.R., Sun L.Q., Khachigian L.M. (2004) Inhibition of human breast carcinoma proliferation, migration, chemoinvasion and solid tumor growth by DNAzymes targeting the zinc finger transcription factor EGR-1. Nucleic Acids Res;32:3065-3069.
27. Dass C.R., Burton M.A. (1999) Lipoplexes and tumours. J Pharm Pharmacol;51:755-770.
28. Dass C.R., Saravolac E.G., Li Y., Sun L.Q. (2002) Cellular uptake, distribution and stability of 10-23 deoxyribozymes. Antisense Nucleic Acid Drug Dev;12:289-299.
29. Walker T.L., Dass C.R., DeCruz E.E., Burton M.A. (1998) A method for intratumoral continuous infusion of antisense oligodeoxynucleotides. J Pharm Sci;87:387-389.
30. Walker T.L., Dass C.R., Burton M.A. (2002) Enhanced in vivo tumour response from combination carboplatin and low dose c-myc antisense oligonucleotides. Anticancer Res;14:2237-2245.
31. Dass C.R. (2004) DNAzymes: cleaving a path to clinical trials. Trends Pharmacol Sci;25:395-397.
32. Bhindi R., Fahmy R.G., Lowe H.C., Chesterman C.N., Dass C.R., Cairns M.J., Saravolac E.G., Sun L.Q., Khachigian L.M. (2007) Brothers in arms: DNA enzymes, short interfering RNA, and the emerging wave of small-molecule nucleic acid-based gene-silencing strategies. Am J Pathol;171:1079-1088.